Approved regimen
Approved labeled regimen
Product-, indication-, and jurisdiction-specific — see the monograph
- Product: SCENESSE (afamelanotide implant) 16 mg
- Route: Subcutaneous implant (above anterior supra-iliac crest) via SFM Implantation Cannula by trained healthcare professional
- Dosing: 16 mg every 2 months
- Duration: As needed for ongoing photoprotection
- Contraindicated in known hypersensitivity to afamelanotide or excipients